Seres Therapeutics
MCRB
36 hedge funds and large institutions have $36.4M invested in Seres Therapeutics in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 5 closing their positions.
189% more call options, than puts
Call options by funds: $6.72M | Put options by funds: $2.33M
100% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 7
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
13% more funds holding
Funds holding: 32 → 36 (+4)
2.71% more ownership
Funds ownership: 24.28% → 26.99% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less capital invested
Capital invested by funds: $40.9M → $36.4M (-$4.53M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.14M |
| 2 |
6CM
683 Capital Management
New York
|
+$912K |
| 3 |
Two Sigma Investments
New York
|
+$449K |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$284K |
| 5 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
+$251K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
-$519K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$147K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$94.6K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$89.8K |
| 5 |
Citigroup
New York
|
-$50.4K |
MCRB Hedge Fund Activity: Q4 2025 in Review
36 of the 8,229 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q4 2025, worth a combined $36.4M — down 11% from $40.9M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new MCRB positions and 5 closed out — a net gain of 4 holders — while 14 added to existing stakes and 7 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $3.14M. The largest seller was J. Goldman & Co, exiting entirely with an estimated $519K sold.
- 36 institutional investors held Seres Therapeutics (MCRB) as of Q4 2025, up from 32 in Q3 2025.
- Funds reported $36.4M of Seres Therapeutics stock for Q4 2025, down 11% quarter-over-quarter.
- 9 funds opened new Seres Therapeutics positions in Q4 2025 and 5 closed out, a net change of +4 holders.
- The largest Seres Therapeutics buyer in Q4 2025 was Susquehanna International Group, an estimated $3.14M added.
- The largest Seres Therapeutics seller in Q4 2025 was J. Goldman & Co, an estimated $519K sold.
Based on aggregated 13F filings for Q4 2025.